{"id":4199,"date":"2026-10-22T18:52:41","date_gmt":"2026-10-22T22:52:41","guid":{"rendered":"https:\/\/canasanta.ca\/?p=4199"},"modified":"2026-10-22T18:52:41","modified_gmt":"2026-10-22T22:52:41","slug":"pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2","status":"publish","type":"post","link":"https:\/\/canasanta.ca\/en\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/","title":{"rendered":"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo"},"content":{"rendered":"

 <\/p>\n

Una p\u00edldora experimental de una toma diaria logr\u00f3 una respuesta cl\u00ednica significativamente mayor que el placebo en pacientes con colitis ulcerosa moderada o grave, seg\u00fan resultados de fase 2 anunciados este lunes 19 de octubre por Gilead Sciences. El f\u00e1rmaco, emvistegrast, todav\u00eda no est\u00e1 aprobado y deber\u00e1 superar ensayos de fase avanzada antes de poder considerarse un tratamiento disponible.<\/h3>\n

Los resultados proceden del estudio SWIFT, un ensayo aleatorizado y controlado con placebo que evalu\u00f3 distintas dosis del inhibidor oral de integrina \u03b14\u03b27 emvistegrast durante una fase de inducci\u00f3n de 12 semanas. Reuters inform\u00f3 del anuncio este lunes y los datos fueron presentados como comunicaci\u00f3n de \u00faltima hora durante la United European Gastroenterology Week 2026 en Barcelona.<\/p>\n

<\/div>\n

El 66% respondi\u00f3 al tratamiento frente al 37% con placebo<\/strong><\/h2>\n

En el grupo que recibi\u00f3 200 miligramos de emvistegrast, el 66% de los participantes \u201433 de 59\u2014 alcanz\u00f3 el criterio principal de respuesta cl\u00ednica a las 12 semanas. En el grupo placebo lo consigui\u00f3 el 37% \u201422 de 60\u2014. La diferencia cumpli\u00f3 el objetivo principal del ensayo.<\/p>\n

La remisi\u00f3n cl\u00ednica, un criterio m\u00e1s exigente que implica un control mucho mayor de la enfermedad, se observ\u00f3 en el 31% de quienes recibieron la dosis de 200 miligramos, frente al 8% de los participantes tratados con placebo. Gilead inform\u00f3 adem\u00e1s de mejoras en otros indicadores de actividad de la enfermedad.<\/p>\n

<\/div>\n

Una v\u00eda conocida, pero ahora mediante una p\u00edldora<\/strong><\/h2>\n

Emvistegrast est\u00e1 dise\u00f1ado para bloquear selectivamente la v\u00eda de la integrina \u03b14\u03b27, un mecanismo ya validado en el tratamiento de la enfermedad inflamatoria intestinal. La diferencia que intenta aportar el candidato de Gilead es hacerlo mediante una terapia oral de administraci\u00f3n diaria.<\/p>\n

La colitis ulcerosa es una enfermedad inflamatoria intestinal cr\u00f3nica y recurrente que provoca inflamaci\u00f3n y \u00falceras en el colon. Aunque existen m\u00faltiples terapias avanzadas, una parte de los pacientes no logra mantener un control sostenido de la enfermedad o pierde respuesta a los tratamientos disponibles.<\/p>\n

<\/div>\n

El perfil de seguridad fue comparable al placebo<\/strong><\/h2>\n

Seg\u00fan los datos comunicados, el medicamento fue generalmente bien tolerado. Reuters se\u00f1al\u00f3 que la frecuencia global de efectos adversos fue comparable entre los grupos tratados y el placebo y que no se relacionaron efectos adversos graves con el medicamento del estudio.<\/p>\n

Ese resultado es relevante, pero todav\u00eda preliminar. El ensayo contin\u00faa y se esperan datos adicionales de la fase de mantenimiento. La eficacia y seguridad de emvistegrast no han sido establecidas para uso cl\u00ednico y el f\u00e1rmaco no est\u00e1 aprobado en ning\u00fan pa\u00eds.<\/p>\n

<\/div>\n

El siguiente paso ser\u00e1 un ensayo de fase avanzada<\/strong><\/h2>\n

Gilead anunci\u00f3 que planea iniciar en 2027 un estudio de fase avanzada que evaluar\u00e1 emvistegrast como monoterapia. Esa etapa deber\u00e1 confirmar en una poblaci\u00f3n mayor si las diferencias observadas en SWIFT se mantienen y si el perfil de seguridad contin\u00faa siendo favorable.<\/p>\n

Los resultados conocidos este lunes no significan que exista ya una nueva cura para la colitis ulcerosa. S\u00ed constituyen una se\u00f1al cl\u00ednica suficientemente s\u00f3lida para justificar el avance del medicamento y abren la posibilidad de una nueva alternativa oral si los pr\u00f3ximos ensayos reproducen los resultados.<\/p>","protected":false},"excerpt":{"rendered":"

  Una p\u00edldora experimental de una toma diaria logr\u00f3 una respuesta cl\u00ednica significativamente mayor que el placebo en pacientes con colitis ulcerosa moderada o grave, seg\u00fan resultados de fase 2 anunciados este lunes 19 de octubre por Gilead Sciences. El f\u00e1rmaco, emvistegrast, todav\u00eda no est\u00e1 aprobado y deber\u00e1 superar ensayos de fase avanzada antes de […]<\/p>\n","protected":false},"author":284226809,"featured_media":5050,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_wpcom_ai_launchpad_first_post":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[33205457,2127],"tags":[33207109,33207110,33207112,33207111],"class_list":["post-4199","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-al-dia","category-salud","tag-colitis-ulcerosa","tag-emvistegrast","tag-enfermedad-inflamatoria-intestinal","tag-gilead-sciences"],"acf":[],"yoast_head":"\nUna p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo - Ca\u00f1asanta<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/canasanta.ca\/en\/health\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo\" \/>\n<meta property=\"og:description\" content=\"  Una p\u00edldora experimental de una toma diaria logr\u00f3 una respuesta cl\u00ednica significativamente mayor que el placebo en pacientes con colitis ulcerosa moderada o grave, seg\u00fan resultados de fase 2 anunciados este lunes 19 de octubre por Gilead Sciences. El f\u00e1rmaco, emvistegrast, todav\u00eda no est\u00e1 aprobado y deber\u00e1 superar ensayos de fase avanzada antes de […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/canasanta.ca\/en\/health\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Ca\u00f1asanta\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-22T22:52:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa-%E2%80%94-imagen-editorial.jpg?resize=1200,630&quality=85&strip=all&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ca\u00f1asanta\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ca\u00f1asanta\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/\"},\"author\":{\"name\":\"Ca\u00f1asanta\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\"},\"headline\":\"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo\",\"datePublished\":\"2026-10-22T22:52:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/\"},\"wordCount\":540,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1\",\"keywords\":[\"colitis ulcerosa\",\"emvistegrast\",\"enfermedad inflamatoria intestinal\",\"Gilead Sciences\"],\"articleSection\":[\"AL D\u00cdA!\",\"Salud\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/\",\"name\":\"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo - Ca\u00f1asanta\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1\",\"datePublished\":\"2026-10-22T22:52:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1\",\"width\":1080,\"height\":720,\"caption\":\"M\u00e9dico conversa con una paciente hospitalizada, imagen editorial para informaci\u00f3n sobre colitis ulcerosa\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AL D\u00cdA!\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/category\\\/al-dia\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"name\":\"Ca\u00f1asanta\",\"description\":\"Magazine\",\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/canasanta.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\",\"name\":\"Ca\u00f1asanta\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1\",\"width\":1500,\"height\":500,\"caption\":\"Ca\u00f1asanta\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\",\"name\":\"Ca\u00f1asanta\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"caption\":\"Ca\u00f1asanta\"},\"sameAs\":[\"http:\\\/\\\/canasantaonline-pbuqn.wordpress.com\"],\"url\":\"https:\\\/\\\/canasanta.ca\\\/en\\\/author\\\/canasantaonline\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo - Ca\u00f1asanta","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/canasanta.ca\/en\/health\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/","og_locale":"en_US","og_type":"article","og_title":"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo","og_description":"  Una p\u00edldora experimental de una toma diaria logr\u00f3 una respuesta cl\u00ednica significativamente mayor que el placebo en pacientes con colitis ulcerosa moderada o grave, seg\u00fan resultados de fase 2 anunciados este lunes 19 de octubre por Gilead Sciences. El f\u00e1rmaco, emvistegrast, todav\u00eda no est\u00e1 aprobado y deber\u00e1 superar ensayos de fase avanzada antes de […]","og_url":"https:\/\/canasanta.ca\/en\/health\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/","og_site_name":"Ca\u00f1asanta","article_published_time":"2026-10-22T22:52:41+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa-%E2%80%94-imagen-editorial.jpg?resize=1200,630&quality=85&strip=all&ssl=1","type":"image\/jpeg"}],"author":"Ca\u00f1asanta","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ca\u00f1asanta","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/#article","isPartOf":{"@id":"https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/"},"author":{"name":"Ca\u00f1asanta","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93"},"headline":"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo","datePublished":"2026-10-22T22:52:41+00:00","mainEntityOfPage":{"@id":"https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/"},"wordCount":540,"commentCount":0,"publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"image":{"@id":"https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1","keywords":["colitis ulcerosa","emvistegrast","enfermedad inflamatoria intestinal","Gilead Sciences"],"articleSection":["AL D\u00cdA!","Salud"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/","url":"https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/","name":"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo - Ca\u00f1asanta","isPartOf":{"@id":"https:\/\/canasanta.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/#primaryimage"},"image":{"@id":"https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1","datePublished":"2026-10-22T22:52:41+00:00","breadcrumb":{"@id":"https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/#primaryimage","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1","width":1080,"height":720,"caption":"M\u00e9dico conversa con una paciente hospitalizada, imagen editorial para informaci\u00f3n sobre colitis ulcerosa"},{"@type":"BreadcrumbList","@id":"https:\/\/canasanta.ca\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/canasanta.ca\/"},{"@type":"ListItem","position":2,"name":"AL D\u00cdA!","item":"https:\/\/canasanta.ca\/category\/al-dia\/"},{"@type":"ListItem","position":3,"name":"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo"}]},{"@type":"WebSite","@id":"https:\/\/canasanta.ca\/#website","url":"https:\/\/canasanta.ca\/","name":"Ca\u00f1asanta","description":"Magazine","publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/canasanta.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/canasanta.ca\/#organization","name":"Ca\u00f1asanta","url":"https:\/\/canasanta.ca\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1","width":1500,"height":500,"caption":"Ca\u00f1asanta"},"image":{"@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93","name":"Ca\u00f1asanta","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","caption":"Ca\u00f1asanta"},"sameAs":["http:\/\/canasantaonline-pbuqn.wordpress.com"],"url":"https:\/\/canasanta.ca\/en\/author\/canasantaonline\/"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/phoxY0-15J","jetpack-related-posts":[{"id":4330,"url":"https:\/\/canasanta.ca\/en\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/","url_meta":{"origin":4199,"position":0},"title":"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa","author":"Ca\u00f1asanta","date":"October 19, 2026","format":false,"excerpt":"Emvistegrast, una terapia oral experimental de Gilead, alcanz\u00f3 respuesta cl\u00ednica en el 66% de los pacientes con colitis ulcerosa moderada o grave frente al 37% con placebo en un ensayo de fase 2.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Medicamentos en una investigaci\u00f3n cl\u00ednica sobre colitis ulcerosa","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4044,"url":"https:\/\/canasanta.ca\/en\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/","url_meta":{"origin":4199,"position":1},"title":"Un f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda","author":"Ca\u00f1asanta","date":"October 18, 2026","format":false,"excerpt":"Un peque\u00f1o ensayo cl\u00ednico de fase 1b encontr\u00f3 que ANB033 redujo el da\u00f1o intestinal y los s\u00edntomas durante una exposici\u00f3n controlada al gluten en pacientes con celiaqu\u00eda.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Pan de trigo sobre una tabla, imagen editorial para un art\u00edculo sobre celiaqu\u00eda y un tratamiento experimental","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4843,"url":"https:\/\/canasanta.ca\/en\/salud\/pildora-experimental-reduce-recaidas-esclerosis-multiple\/","url_meta":{"origin":4199,"position":2},"title":"Una p\u00edldora experimental reduce un 55% las reca\u00eddas de esclerosis m\u00faltiple","author":"Ca\u00f1asanta","date":"October 21, 2026","format":false,"excerpt":"Fenebrutinib, el tratamiento oral experimental de Roche, redujo un 55% las reca\u00eddas de esclerosis m\u00faltiple en ensayos de fase avanzada y mostr\u00f3 efectos sobre la progresi\u00f3n de la enfermedad.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Especialistas m\u00e9dicos examinan im\u00e1genes cerebrales durante una evaluaci\u00f3n neurol\u00f3gica","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4518,"url":"https:\/\/canasanta.ca\/en\/salud\/tezepelumab-remision-esofagitis-eosinofilica\/","url_meta":{"origin":4199,"position":3},"title":"UN F\u00c1RMACO LOGRA 69% DE REMISI\u00d3N EN UNA ENFERMEDAD DEL ES\u00d3FAGO","author":"Ca\u00f1asanta","date":"October 20, 2026","format":false,"excerpt":"Tezepelumab logr\u00f3 remisi\u00f3n histol\u00f3gica en hasta el 68,9% de pacientes con esofagitis eosinof\u00edlica en un ensayo fase 3 y redujo la dificultad para tragar.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Imagen endosc\u00f3pica de un es\u00f3fago con la estructura anular caracter\u00edstica de la esofagitis eosinof\u00edlica","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esofagitis-eosinofilica-%E2%80%94-endoscopia.jpg?fit=1200%2C933&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esofagitis-eosinofilica-%E2%80%94-endoscopia.jpg?fit=1200%2C933&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esofagitis-eosinofilica-%E2%80%94-endoscopia.jpg?fit=1200%2C933&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esofagitis-eosinofilica-%E2%80%94-endoscopia.jpg?fit=1200%2C933&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esofagitis-eosinofilica-%E2%80%94-endoscopia.jpg?fit=1200%2C933&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":1891,"url":"https:\/\/canasanta.ca\/en\/al-dia\/la-inyeccion-que-hace-perder-21-del-peso\/","url_meta":{"origin":4199,"position":4},"title":"THE INJECTION THAT CAUSES YOU TO LOSE 21% OF WEIGHT","author":"Ca\u00f1asanta","date":"September 29, 2026","format":false,"excerpt":"Un nuevo f\u00e1rmaco experimental de Eli Lilly logra una p\u00e9rdida media cercana a 50 libras en pacientes con obesidad y diabetes tipo 2. Los resultados de fase 3 colocan a retatrutide entre los tratamientos para adelgazar m\u00e1s potentes estudiados hasta ahora. Eli Lilly acaba de presentar nuevos resultados de retatrutide,\u2026","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"CS inyeccion diabetes001","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4189,"url":"https:\/\/canasanta.ca\/en\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/","url_meta":{"origin":4199,"position":5},"title":"Merck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras","author":"Ca\u00f1asanta","date":"October 19, 2026","format":false,"excerpt":"La alemana Merck KGaA anunci\u00f3 este lunes 19 de octubre un acuerdo para adquirir Silence Therapeutics por aproximadamente 1.300 millones de d\u00f3lares, una operaci\u00f3n que incorpora a su cartera una plataforma de ARN interferente y un tratamiento experimental avanzado para la policitemia vera, un raro c\u00e1ncer de la sangre. El\u2026","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Laboratorio de investigaci\u00f3n gen\u00e9tica y secuenciaci\u00f3n, imagen editorial sobre terapias siRNA y la adquisici\u00f3n de Silence Therapeutics","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]}],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1","_links":{"self":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/4199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/users\/284226809"}],"replies":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/comments?post=4199"}],"version-history":[{"count":2,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/4199\/revisions"}],"predecessor-version":[{"id":5046,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/4199\/revisions\/5046"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media\/5050"}],"wp:attachment":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media?parent=4199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/categories?post=4199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/tags?post=4199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}